Last reviewed · How we verify
NCT02786082
Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers
Phase 1 trial testing 20mg Azilsartan Tablets in Hypertension in 29 participants. Completed in 30 November 2017.
31 August 2017
Quick facts
| Lead sponsor | Lee's Pharmaceutical Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 1 November 2016 |
| Primary completion | 31 August 2017 |
| Estimated completion | 30 November 2017 |
Drugs / interventions tested
- 20mg Azilsartan Tablets — full drug profile →
- 40mg Azilsartan Tablets — full drug profile →
Conditions studied
- Hypertension — all drugs for Hypertension →
Sponsor
Lee's Pharmaceutical Limited — full company profile →
Who can join
Adults 18 to 45, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective is to study the pharmacokinetics of Azilsartan Tablets in human and providing evidence for clinical study and clinical application of this product.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02786082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Lee's Pharmaceutical Limited trials
Trials by the same sponsor.
- NCT06953453 — A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors · Phase 1 · recruiting
- NCT07099144 — Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension · recruiting
- NCT06459687 — Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer · Phase 3 · recruiting
- NCT06374485 — Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment · Phase 1 · recruiting
- NCT05806918 — Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient M · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02786082 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lee's Pharmaceutical Limited
- Last refreshed: 5 September 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02786082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing